The trial asked a tissue-level question
Loomba and colleagues randomized 190 adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis, or MASH, and stage 2 or 3 fibrosis. The blinded phase 2 trial compared tirzepatide with placebo over 52 weeks. Its primary outcome required MASH resolution without worsening fibrosis, so both parts mattered.
Keep the endpoint intact
The primary outcome occurred in 44% to 62% of the tirzepatide groups, compared with 10% with placebo. Improvement of at least one fibrosis stage without worsening MASH was a different, secondary outcome. End-of-study biopsies were evaluable for 157 participants; missing results were imputed using an assumption based on the placebo group. Gastrointestinal adverse events were most common with tirzepatide.
What a reader should check
In a compound claim, words such as resolution, improvement and cure should not be used interchangeably. Ask what tissue feature changed, whether another feature was required to remain stable, and what happened to participants without a final measurement. A percentage is much more informative when its definition and denominator remain visible.
A promising result with a bounded meaning
These findings do not establish fewer liver transplants, better survival or permanent disease resolution. The authors called for larger, longer trials. We reviewed the indexed abstract and bibliographic record; the publisher full-text route was unavailable. This Eli Lilly-funded 2024 study is newly featured today. It neither provides a self-treatment plan nor establishes equivalence between catalog research materials and the trial product.